Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ophthalmic Immune-Related Adverse Events in Cancer Immunotherapy: Tissue-Specific Mechanisms, Clinical Phenotypes, and Consensus-Based Management.

International journal of molecular sciences - 1 Jul 2026

Zong Yuan, Yang Mingming, Zhang Jing, Zou Yaru, Ye Zizhen, Deng Jiaxin, Gu Wendong, Ohno-Matsui Kyoko, Kamoi Koju

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by restoring anti-tumor immunity, but immune activation can disrupt ocular immune homeostasis and induce ophthalmic immune-related adverse events (OirAEs). Although uncommon, OirAEs may involve nearly all ocular compartments and can cause irreversible visual impairment or interruption of effective anticancer therapy. The 2025 international...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eye
Share to Eye Diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Neoplasms

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 42450211
DOI: 10.3390/ijms27135944
PMCID: PMC13361132

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ophthalmic Immune-Related Adverse Events in Cancer Immunotherapy: Tissue-Specific Mechanisms, Clinical Phenotypes, and Consensus-Based Management.PMID 42450211Read ↗

Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based TherapiesSemantic proximity Read ↗

Advances in immunotherapy for uveal melanoma: enhancing efficacy and overcoming resistanceSemantic proximity Read ↗

Recent advances in ocular graft-versus-host diseaseSemantic proximity Read ↗

Conjunctival Melanoma: Current Treatments and Future Options.Semantic proximity Read ↗

Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity Read ↗

Malignancies in Immunoglobulin G4-Related Ophthalmic DiseaseSemantic proximity Read ↗

Conjunctival Squamous Cell Carcinoma: A Clinical Review of Diagnostic Features, Genetics, Current Management and an Update on Targeted and ImmunotherapiesSemantic proximity Read ↗

Comprehensive Analysis of the Immune Cell Infiltration Landscape and Immune-Related Methylation in RetinoblastomaSemantic proximity Read ↗

Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.Semantic proximity Read ↗

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review.Semantic proximity Read ↗

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.Semantic proximity Read ↗

Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.